Search for data related to genes or regions
+
66 Study Datasets reported containing markers in gene or region ADAM19 (no 5′ and no 3′ flanks) with -log p ≥ 0 (showing 1-50)
Pages: 1 2
No data sets (in No Phenotypes) added to Browser
Phenotype tested in Study Phenotype ontology annotation Total p-values in Study StudyAdd data sets to Browser Related Study data
4 kHz hearing threshold (HGVPM567)
  • Hearing
959,443 GWAS of 4 kHz hearing threshold in a British population (HGVST311)
Adult height (HGVPM565)
  • Body Height
959,443 GWAS of height in a British population (HGVST309)
Age-related macular degeneration (HGVPM6)
  • Macular Degeneration
427,832 GWAS of age-related macular degeneration (HGVST4)
Age-related macular degeneration (HGVPM771)
  • Macular Degeneration
324,068 GWAS of age-related macular degeneration (HGVST435)
Alzheimer's disease (HGVPM72)
  • Alzheimer Disease
477,838 GWAS of Alzheimer's disease (HGVST51)
Amyotrophic lateral sclerosis (HGVPM96)
  • Amyotrophic Lateral Sclerosis
512,741 GWAS of amyotrophic lateral sclerosis (HGVST65)
Amyotrophic lateral sclerosis (HGVPM40)
  • Amyotrophic Lateral Sclerosis
512,009 GWAS of sporadic amyotrophic lateral sclerosis in a homogenous Irish population (HGVST29)
Anti-cyclic citrullinated peptide-positive rheumatoid arthritis (HGVPM38)
  • Arthritis, Rheumatoid
297,085 GWAS of rheumatoid arthritis (HGVST27)
Asthma (HGVPM1101)
  • Asthma
546,180 GWAS of asthma (HGVST631)
Bipolar disorder (HGVPM1512)
  • Bipolar Disorder
699,461 Whole Genome Association Study of bipolar disorder (HGVST889)
Bipolar disorder (HGVPM1513)
  • Bipolar Disorder
809,854 Whole Genome Association Study of bipolar disorder (HGVST889)
Bipolar disorder (HGVPM837)
  • Bipolar Disorder
1 GWAS of bipolar disorder in European American and African American individuals (HGVST472)
Birth weight (HGVPM571)
  • Birth Weight
959,443 GWAS of birth weight in a British population (HGVST315)
Body mass index (HGVPM1111)
  • Body Mass Index
38 GWAS of body mass index (HGVST640)
Body mass index (HGVPM564)
  • Body Mass Index
959,443 GWAS of adult body mass index in a British population (HGVST308)
Brain glutamate concentrations (HGVPM1065)
  • Glutamic Acid
  • Multiple Sclerosis
  • Brain
5 GWAS of patients with multiple sclerosis using brain glutamate concentration as a quantitative trait (HGVST605)
Breast cancer (HGVPM2)
  • Breast Neoplasms
1,074,608 GWAS of breast cancer (HGVST2)
Coronary artery disease (HGVPM113)
  • Coronary Artery Disease
1,059 GWAS of coronary artery disease (HGVST75)
Crohn's disease (HGVPM1169)
  • Crohn Disease
50 GWAS of Crohn's disease (HGVST680)
Diabetic nephropathy in type I diabetes (HGVPM1531)
  • Diabetic Nephropathies
706,749 Genetics of kidneys in diabetes (GoKinD) (HGVST890)
Diabetic nephropathy in type I diabetes (HGVPM1524)
  • Diabetic Nephropathies
358,475 Genetics of kidneys in diabetes (GoKinD) (HGVST890)
Ethanol (HGVPM3609)
  • Ethanol
2,479 GWAS of Metabolite quantitative traits (HGVST1827)
Fasting glucose-related: fasting plasma glucose (HGVPM825)
  • Blood Glucose
16 GWAS of glycemic traits (HGVST463)
Fasting glucose-related: homeostatic model assessment of beta-cell function (HGVPM827)
  • Insulin-Secreting Cells
10 GWAS of glycemic traits (HGVST463)
Fasting insulin-related: fasting insulin (HGVPM822)
  • Insulin
2 GWAS of glycemic traits (HGVST463)
Fasting insulin-related: homeostatic model assessment of insulin resistance (HGVPM826)
  • Insulin Resistance
2 GWAS of glycemic traits (HGVST463)
Flucloxacillin-induced liver injury (HGVPM153)
  • Drug-Induced Liver Injury
868,330 GWAS of drug-induced liver injury due to flucloxacillin (HGVST107)
Forced expiratory volume (HGVPM916)
  • Forced Expiratory Volume
3,000 GWAS of lung function (HGVST513)
Glycated hemoglobin levels (HGVPM1081)
  • Hemoglobin A, Glycosylated
11 GWAS of glycated hemoglobin levels (HGVST618)
Height (HGVPM1104)
  • Body Height
2,469,620 GWAS of height (HGVST634)
Height-adjusted highest forced expiratory volume (HGVPM566)
  • Forced Expiratory Volume
959,443 GWAS of height-adjusted highest forced expiratory volume in a British population (HGVST310)
Hodgkin lymphoma (HGVPM3588)
  • Hodgkin Disease
584,850 GWAS of Hodgkin lymphoma (HGVST1823)
Ischemic stroke (HGVPM20)
  • Stroke
786,560 GWAS of ischemic stroke (HGVST14)
Kuru (HGVPM3053)
  • Kuru
0 GWAS of prion diseases (HGVST1013)
Log10 fibrinogen (HGVPM570)
  • Fibrinogen
959,443 GWAS of log10 fibrinogen in a British population (HGVST314)
Log10 glycosylated haemoglobin (HGVPM569)
  • Hemoglobin A, Glycosylated
959,443 GWAS of log10 glycosylated haemoglobin in a British population (HGVST313)
Log10 serum total immunoglobulin E concentration (HGVPM562)
  • Immunoglobulin E
959,443 GWAS of log10 serum total immunoglobulin E concentration in a British population (HGVST306)
Narcolepsy (HGVPM165)
  • Narcolepsy
244,737 GWAS of narcolepsy in a Japanese population (HGVST115)
Nephropathy (HGVPM994)
  • Glomerulonephritis, IGA
286,197 GWAS of nephropathy (HGVST558)
Neuropathic pain-like symptoms (HGVPM3681)
  • Neuralgia
5,492 GWAS of neuropathic pain-like symptoms (HGVST1846)
Nose profile (HGVPM3666)
  • Nose
10,155 GWAS of Facial features (HGVST1841)
Parkinson's disease (HGVPM3)
  • Parkinson Disease
792,112 GWAS of Parkinson's disease (HGVST6)
Parkinson's disease (HGVPM126)
  • Parkinson Disease
192,227 GWAS of Parkinson's disease (HGVST83)
Partial epilepsies (HGVPM929)
  • Epilepsies, Partial
528,036 GWAS of partial epilepsies (HGVST522)
Proinsulin levels (HGVPM1538)
  • Proinsulin
10 GWAS of proinsulin levels (HGVST907)
Prostate cancer (HGVPM1)
  • Prostatic Neoplasms
1,682,332 GWAS of prostate cancer (HGVST1)
Psoriasis (HGVPM1532)
  • Psoriasis
440,151 GWAS of psoriasis (HGVST902)
Pulmonary function (FEV1) (HGVPM1597)
  • Respiratory Function Tests
2,419,132 GWAS of pulmonary function (HGVST946)
Pulmonary function (FEV1/FVC) (HGVPM1596)
  • Respiratory Function Tests
2,419,132 GWAS of pulmonary function (HGVST946)
Response to antipsychotic therapy, extrapyramidal side effects: abnormal involuntary movement scale (HGVPM820)
  • Antipsychotic Agents
479,554 GWAS of movement-related adverse antipsychotic effects (HGVST461)